In vitro
Salidroside is the major active component of Rhodiola rosea, a herb with antioxidant, free radical scavenging and tyrosinase inhibitory effects. The significant inhibition of salidroside (33.0%) and paeonol (22.2-30.9%) on the tyrosinase activity is slightly lower than that of arbutin (18.4-44.7%).Salidroside exhibited the dose-dependent inhibition (30.6-42.0%) in melanin synthesis at a low concentration of 100uM, paeonol and arbutin expressed inhibition rates of 27.4-37.2% and 25.8-45.6% within 500-1000uM. [1] Salidroside has been used as an antioxidative therapy for oxidative injury in cardiac diseases. salidroside is capable of protecting HUVECs against H2O2-induced apoptosis by activating the PI3K/Akt/mTOR-dependent pathway and inhibiting ROS production by activating REDD1.[2] Salidroside inhibits homocystein-induced elevation in the NOX2 expression and ROS overproduction in both aortas and cultured endothelial cells and increass phosphorylation of eNOS which is diminished by homocysteine. Salidroside is effective in preserving the NO bioavailability and thus protects against homocysteine-induced impairment of endothelium-dependent relaxations, largely through inhibiting the NOX2 expression and ROS production. [3]
Download Datasheet